Roche

Valuation Analysis

About the Company

Roche en bref

Roche (ROG.SW) is currently trading at 322,30 CHF with a market capitalization of 223,8 Md €. The trailing P/E ratio stands at 20.11x, with a forward P/E of 14.82x. The 52-week range spans from 231,90 CHF to 374,90 CHF ; the current price is 14% below the yearly high. Year-over-year revenue growth stands at -0.4%. The net profit margin stands at 20.33%.

💰 Dividende

Roche pays an annual dividend of 9,80 CHF per share, representing a yield of 3.04%. The payout ratio stands at 60.47%.

📊 Avis des analystes

19 analystes évaluent Roche (ROG.SW) au consensus : Acheter. L'objectif de cours moyen est de 364,79 CHF , soit un potentiel de +13.18% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 230,00 CHF à 428,00 CHF .

Roche : la thèse d'investissement en détail

Roche (ROG.SW) operates in the Healthcare — specifically Drug Manufacturers - General — and is headquartered in Switzerland. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Earnings growth of 171.3% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. With a gross margin near 74.49%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Return on equity of 37.27% places management among the most capital-efficient operators in the public market — every euro of shareholder capital is working hard.

Le scénario baissier

Revenue is contracting at -0.4% year-over-year — until that trend reverses, valuation is exposed to further downgrades.

À surveiller

• The forward P/E of 14.82x is meaningfully below the trailing 20.11x — analysts expect earnings to step up; the next earnings release is the test.
• The dividend yield near 3.04% combined with a payout ratio of 60.47% leaves room for further hikes — a track record of consecutive raises is a strong income signal.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price shows short-term weakness (below 50d MA) but is still in a longer-term uptrend (above 200d MA).

Profil de risque

The data points to relatively defensive market behavior.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Roche?

Compare top-rated brokers — low fees, trusted providers, fully regulated.